2-P-186

Poster Sessions

Galantamine inhibits aggregation of α -synuclein in human neuroblastoma SH-SY5Y cellsSora Nozaki, Masanori Hijioka, Masahisa Tsuji, Yoshihisa Kitamura*Lab. Pharmacology and Neurobiology, College of Pharmaceutical Sciences, Ritsumeikan University*

Synucleinopathies such as Parkinson's disease (PD) and dementia with Lewy bodies (DLB) are neurodegenerative disorders featured by the abnormal accumulation of α -synuclein protein (α -syn). Recent studies showed exogenous pre-formed fibrils (PFFs) of recombinant α -syn induced endogenous α -syn aggregates in human SH-SY5Y cells. In this study, we focused on nicotinic acetylcholine receptor (nAChR) as the therapeutic targets for synucleinopathies through α -syn clearance. PFFs were generated from α -syn by agitation followed by sonication. SH-SY5Y cells overexpressing α -syn gene were treated with PFFs for 24 h. After the incubation for 48 h, immunocytochemical analysis revealed the localization of α -syn. PFFs induced the aggregation of α -syn, which were detected with anti-phosphorylated- α -syn antibody and thioflavin-T. These data indicated that intracellular aggregation of α -syn were Lewy body-like aggregates. In addition, we examined galantamine effect, because some reports showed nAChR signaling increased autophagic activity. Galantamine were treated for 48 h after preincubation with PFFs, and then α -syn aggregation was decreased. These observations suggest that nAChR may be a novel target for synucleinopathies through α -syn clearance by autophagic activation.